During the validation study of the EPSILoN scoring system among patients with locally advanced NSCLC who underwent anti-PD-1 immunotherapy, participants were divided into high, moderate, and low-risk groups (122). The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.